GLP-1 treatment for diabetes and obesity Semaglutide, a GLP-1 receptor agonist, is the active ingredient in Ozempic for diabetes and in Wegovy for obesity
The delayed gastric emptying induced by these medications can cause: Prolonged fullness and early satiety Nausea and occasional vomiting Altered oral and esophageal sensations Potential changes in oral sensations These gastrointestinal symptoms can create conditioned taste aversions, where the brain associates certain foods with discomfort, leading to reduced palatability
The common ones include: BPC-157: accelerates tissue healing, increases blood flow to injured parts of the body, heals skin burns, prevents stomach ulcers, and protects organs
Taking too much can lead to unnecessary digestive distress and mineral imbalances like zinc depletion
GLP-1 (glucagon-like peptide-1) medications, such as semaglutide and tirzepatide, work by regulating appetite, slowing digestion, and improving blood sugar control